Epinephrine use in older patients with anaphylaxis: Clinical outcomes and cardiovascular complications

Resuscitation

Volumn 112, Issue , 2017, Pages 53-58

  Kawano, Takahisa ^a,b   Scheuermeyer, Frank Xavier ^a,c   Stenstrom, Robert ^a,c   Rowe, Brian H ^d   Grafstein, Eric ^a,c   Grunau, Brian ^a,c  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF FUKUI HOSPITAL   (Japan)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Anaphylaxis; Cardiovascular complications; Emergency department; Epinephrine; Older patients

Indexed keywords

EPINEPHRINE;

ADOLESCENT; ADULT; ALLERGY; ANAPHYLAXIS; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL OUTCOME; COHORT ANALYSIS; DRUG USE; EMERGENCY WARD; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERSONAL EXPERIENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; AGE DISTRIBUTION; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; HEART DISEASE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MEDICATION ERROR; MULTICENTER STUDY; RISK FACTOR; STATISTICAL MODEL;

ADMINISTRATION, INTRAVENOUS; ADULT; AGE DISTRIBUTION; AGED; ANAPHYLAXIS; EPINEPHRINE; FEMALE; HEART DISEASES; HUMANS; INJECTIONS, INTRAMUSCULAR; LOGISTIC MODELS; MALE; MEDICATION ERRORS; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 85009985633     PISSN: 03009572     EISSN: 18731570     Source Type: Journal    
DOI: 10.1016/j.resuscitation.2016.12.020     Document Type: Article

References (21)

1. 1 Sampson, H.A., Munoz-Furlong, A., Campbell, R.L., et al. Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 117 (2006), 391–397.
2. 2 Sampson, H.A., Munoz-Furlong, A., Bock, S.A., et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 115 (2005), 584–591.
3. 3 Lieberman, P., Camargo, C.A. Jr., Bohlke, K., et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol 97 (2006), 596–602.
4. 4 Decker, W.W., Campbell, R.L., Manivannan, V., et al. The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol 122 (2008), 1161–1165.
5. 5 Gaeta, T.J., Clark, S., Pelletier, A.J., Camargo, C.A., National study of US emergency department visits for acute allergic reactions, 1993 to 2004. Ann Allergy Asthma Immunol 98 (2007), 360–365.
6. 6 Simons, F.E., Ardusso, L.R., Bilo, M.B., et al. World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J 4 (2011), 13–37.
7. 7 Campbell, R.L., Hagan, J.B., Li, J.T., et al. Anaphylaxis in emergency department patients 50 or 65 years or older. Ann Allergy Asthma Immunol 106 (2011), 401–406.
8. 8 Cydulka, R., Davison, R., Grammer, L., Parker, M., Mathews, J. 4th, The use of epinephrine in the treatment of older adult asthmatics. Ann Emerg Med 17 (1988), 322–326.
9. 9 Services BCEH, A mobile reference for the BCAS Treatment Guidelines. 2015, British Columbia Emergency Health Services.
10. 10 Grunau, B.E., Wiens, M.O., Rowe, B.H., et al. Emergency department corticosteroid use for allergy or anaphylaxis is not associated with decreased relapses. Ann Emerg Med 66 (2015), 381–389.
11. 11 Grunau, B.E., Li, J., Yi, T.W., et al. Incidence of clinically important biphasic reactions in emergency department patients with allergic reactions or anaphylaxis. Ann Emerg Med 63 (2014), 736–744 e2.
12. 12 Gilbert, E.H., Lowenstein, S.R., Koziol-McLain, J., Barta, D.C., Steiner, J., Chart reviews in emergency medicine research: where are the methods. Ann Emerg Med 27 (1996), 305–308.
13. 13 Worster, A., Bledsoe, R.D., Cleve, P., Fernandes, C.M., Upadhye, S., Eva, K., Reassessing the methods of medical record review studies in emergency medicine research. Ann Emerg Med 45 (2005), 448–451.
14. 14 Brown, S.G., Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 114 (2004), 371–376.
15. 15 Simons, F.E., Ardusso, L.R., Dimov, V., et al. World Allergy Organization Anaphylaxis Guidelines: 2013 update of the evidence base. Int Arch Allergy Immunol 162 (2013), 193–204.
16. 16 Vanden Hoek, T.L., Morrison, L.J., Shuster, M., et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 122 (2010), S829–61.
17. 17 Soar, J., Pumphrey, R., Cant, A., et al. Emergency treatment of anaphylactic reactions—guidelines for healthcare providers. Resuscitation 77 (2008), 157–169.
18. 18 Campbell, R.L., Bellolio, M.F., Knutson, B.D., et al. Epinephrine in anaphylaxis: higher risk of cardiovascular complications and overdose after administration of intravenous bolus epinephrine compared with intramuscular epinephrine. J Allergy Clin Immunol Pract 3 (2015), 76–80.
19. 19 Van de Werf, F., Bax, J., Betriu, A., et al. ESC guidelines on management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Rev Esp Cardiol 62:293 (2009), e1–47.
20. 20 Armitage, P., Tests for linear trends in proportions and frequencies. Biometrics 11 (1955), 375–386.
21. 21 Mulla, Z.D., Simon, M.R., Hospitalizations for anaphylaxis in Florida: epidemiologic analysis of a population-based dataset. Int Arch Allergy Immunol 144 (2007), 128–136.